JP2017502088A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017502088A5 JP2017502088A5 JP2016563278A JP2016563278A JP2017502088A5 JP 2017502088 A5 JP2017502088 A5 JP 2017502088A5 JP 2016563278 A JP2016563278 A JP 2016563278A JP 2016563278 A JP2016563278 A JP 2016563278A JP 2017502088 A5 JP2017502088 A5 JP 2017502088A5
- Authority
- JP
- Japan
- Prior art keywords
- disease
- chronic
- syndrome
- lymphoma
- cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 16
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 13
- 230000001684 chronic effect Effects 0.000 claims 11
- 206010028980 Neoplasm Diseases 0.000 claims 10
- 201000010099 disease Diseases 0.000 claims 9
- 206010025323 Lymphomas Diseases 0.000 claims 8
- 125000000217 alkyl group Chemical group 0.000 claims 8
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 claims 8
- 150000003839 salts Chemical class 0.000 claims 8
- 201000011510 cancer Diseases 0.000 claims 7
- 125000001475 halogen functional group Chemical group 0.000 claims 7
- 125000000623 heterocyclic group Chemical group 0.000 claims 7
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 claims 6
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 6
- 206010020751 Hypersensitivity Diseases 0.000 claims 5
- 201000002481 Myositis Diseases 0.000 claims 5
- 208000026935 allergic disease Diseases 0.000 claims 5
- 229910052739 hydrogen Inorganic materials 0.000 claims 5
- 239000001257 hydrogen Substances 0.000 claims 5
- 125000001424 substituent group Chemical group 0.000 claims 5
- 208000011691 Burkitt lymphomas Diseases 0.000 claims 4
- 208000015943 Coeliac disease Diseases 0.000 claims 4
- 206010010741 Conjunctivitis Diseases 0.000 claims 4
- 208000004232 Enteritis Diseases 0.000 claims 4
- 201000005569 Gout Diseases 0.000 claims 4
- 208000003456 Juvenile Arthritis Diseases 0.000 claims 4
- 206010059176 Juvenile idiopathic arthritis Diseases 0.000 claims 4
- 208000002193 Pain Diseases 0.000 claims 4
- 206010035664 Pneumonia Diseases 0.000 claims 4
- 201000004681 Psoriasis Diseases 0.000 claims 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims 4
- 230000001363 autoimmune Effects 0.000 claims 4
- 208000035475 disorder Diseases 0.000 claims 4
- 201000001155 extrinsic allergic alveolitis Diseases 0.000 claims 4
- 150000002431 hydrogen Chemical class 0.000 claims 4
- 208000022098 hypersensitivity pneumonitis Diseases 0.000 claims 4
- 208000027866 inflammatory disease Diseases 0.000 claims 4
- 201000002215 juvenile rheumatoid arthritis Diseases 0.000 claims 4
- 208000017169 kidney disease Diseases 0.000 claims 4
- 206010025135 lupus erythematosus Diseases 0.000 claims 4
- 210000002307 prostate Anatomy 0.000 claims 4
- 201000009890 sinusitis Diseases 0.000 claims 4
- 208000011580 syndromic disease Diseases 0.000 claims 4
- 230000009885 systemic effect Effects 0.000 claims 4
- -1 1H-tetrazolyl Chemical group 0.000 claims 3
- 206010009900 Colitis ulcerative Diseases 0.000 claims 3
- 208000029523 Interstitial Lung disease Diseases 0.000 claims 3
- 201000011152 Pemphigus Diseases 0.000 claims 3
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 3
- 206010047115 Vasculitis Diseases 0.000 claims 3
- 239000002253 acid Substances 0.000 claims 3
- 125000002252 acyl group Chemical group 0.000 claims 3
- 125000003545 alkoxy group Chemical group 0.000 claims 3
- 230000007815 allergy Effects 0.000 claims 3
- 206010009887 colitis Diseases 0.000 claims 3
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims 3
- 210000004072 lung Anatomy 0.000 claims 3
- 201000006417 multiple sclerosis Diseases 0.000 claims 3
- 210000003739 neck Anatomy 0.000 claims 3
- 201000008383 nephritis Diseases 0.000 claims 3
- 125000003386 piperidinyl group Chemical group 0.000 claims 3
- 125000003226 pyrazolyl group Chemical group 0.000 claims 3
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims 3
- 210000003491 skin Anatomy 0.000 claims 3
- 206010056508 Acquired epidermolysis bullosa Diseases 0.000 claims 2
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims 2
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims 2
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims 2
- 208000026872 Addison Disease Diseases 0.000 claims 2
- 208000003200 Adenoma Diseases 0.000 claims 2
- 206010001233 Adenoma benign Diseases 0.000 claims 2
- 208000022309 Alcoholic Liver disease Diseases 0.000 claims 2
- 206010001889 Alveolitis Diseases 0.000 claims 2
- 206010002198 Anaphylactic reaction Diseases 0.000 claims 2
- 208000032467 Aplastic anaemia Diseases 0.000 claims 2
- 206010003011 Appendicitis Diseases 0.000 claims 2
- 206010003591 Ataxia Diseases 0.000 claims 2
- 208000023275 Autoimmune disease Diseases 0.000 claims 2
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims 2
- 208000032568 B-cell prolymphocytic leukaemia Diseases 0.000 claims 2
- 208000009137 Behcet syndrome Diseases 0.000 claims 2
- 208000008439 Biliary Liver Cirrhosis Diseases 0.000 claims 2
- 208000033222 Biliary cirrhosis primary Diseases 0.000 claims 2
- 208000019838 Blood disease Diseases 0.000 claims 2
- 208000020084 Bone disease Diseases 0.000 claims 2
- 206010006187 Breast cancer Diseases 0.000 claims 2
- 208000026310 Breast neoplasm Diseases 0.000 claims 2
- 206010006448 Bronchiolitis Diseases 0.000 claims 2
- 208000023611 Burkitt leukaemia Diseases 0.000 claims 2
- 206010007558 Cardiac failure chronic Diseases 0.000 claims 2
- 206010007572 Cardiac hypertrophy Diseases 0.000 claims 2
- 208000006029 Cardiomegaly Diseases 0.000 claims 2
- 208000024172 Cardiovascular disease Diseases 0.000 claims 2
- 206010008909 Chronic Hepatitis Diseases 0.000 claims 2
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 2
- 208000011231 Crohn disease Diseases 0.000 claims 2
- 201000003883 Cystic fibrosis Diseases 0.000 claims 2
- 201000004624 Dermatitis Diseases 0.000 claims 2
- 206010012438 Dermatitis atopic Diseases 0.000 claims 2
- 241001317099 Dystaxia Species 0.000 claims 2
- 201000009273 Endometriosis Diseases 0.000 claims 2
- 208000004145 Endometritis Diseases 0.000 claims 2
- 201000011275 Epicondylitis Diseases 0.000 claims 2
- 206010015218 Erythema multiforme Diseases 0.000 claims 2
- 206010016228 Fasciitis Diseases 0.000 claims 2
- 208000001362 Fetal Growth Retardation Diseases 0.000 claims 2
- 206010070531 Foetal growth restriction Diseases 0.000 claims 2
- 208000004463 Follicular Adenocarcinoma Diseases 0.000 claims 2
- 206010061968 Gastric neoplasm Diseases 0.000 claims 2
- 208000007882 Gastritis Diseases 0.000 claims 2
- 208000005577 Gastroenteritis Diseases 0.000 claims 2
- 208000010412 Glaucoma Diseases 0.000 claims 2
- 208000022461 Glomerular disease Diseases 0.000 claims 2
- 206010018364 Glomerulonephritis Diseases 0.000 claims 2
- 206010018634 Gouty Arthritis Diseases 0.000 claims 2
- 206010072579 Granulomatosis with polyangiitis Diseases 0.000 claims 2
- 208000015023 Graves' disease Diseases 0.000 claims 2
- 206010019233 Headaches Diseases 0.000 claims 2
- 208000002250 Hematologic Neoplasms Diseases 0.000 claims 2
- 206010019755 Hepatitis chronic active Diseases 0.000 claims 2
- 101000977771 Homo sapiens Interleukin-1 receptor-associated kinase 4 Proteins 0.000 claims 2
- 208000035150 Hypercholesterolemia Diseases 0.000 claims 2
- 206010021245 Idiopathic thrombocytopenic purpura Diseases 0.000 claims 2
- 208000010159 IgA glomerulonephritis Diseases 0.000 claims 2
- 208000026350 Inborn Genetic disease Diseases 0.000 claims 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 2
- 102100023533 Interleukin-1 receptor-associated kinase 4 Human genes 0.000 claims 2
- 208000005615 Interstitial Cystitis Diseases 0.000 claims 2
- 201000008197 Laryngitis Diseases 0.000 claims 2
- 206010024238 Leptospirosis Diseases 0.000 claims 2
- 208000004852 Lung Injury Diseases 0.000 claims 2
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims 2
- 206010052178 Lymphocytic lymphoma Diseases 0.000 claims 2
- 201000009906 Meningitis Diseases 0.000 claims 2
- 206010027406 Mesothelioma Diseases 0.000 claims 2
- 208000034578 Multiple myelomas Diseases 0.000 claims 2
- 206010028289 Muscle atrophy Diseases 0.000 claims 2
- 208000003926 Myelitis Diseases 0.000 claims 2
- 208000009525 Myocarditis Diseases 0.000 claims 2
- 206010029164 Nephrotic syndrome Diseases 0.000 claims 2
- 206010029260 Neuroblastoma Diseases 0.000 claims 2
- 208000008589 Obesity Diseases 0.000 claims 2
- 208000010191 Osteitis Deformans Diseases 0.000 claims 2
- 208000005141 Otitis Diseases 0.000 claims 2
- 208000027868 Paget disease Diseases 0.000 claims 2
- 206010033645 Pancreatitis Diseases 0.000 claims 2
- 206010034277 Pemphigoid Diseases 0.000 claims 2
- 241000721454 Pemphigus Species 0.000 claims 2
- 201000007100 Pharyngitis Diseases 0.000 claims 2
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 2
- 208000007452 Plasmacytoma Diseases 0.000 claims 2
- 206010035742 Pneumonitis Diseases 0.000 claims 2
- 206010065159 Polychondritis Diseases 0.000 claims 2
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims 2
- 208000012654 Primary biliary cholangitis Diseases 0.000 claims 2
- 206010036790 Productive cough Diseases 0.000 claims 2
- 208000035416 Prolymphocytic B-Cell Leukemia Diseases 0.000 claims 2
- 201000001263 Psoriatic Arthritis Diseases 0.000 claims 2
- 208000036824 Psoriatic arthropathy Diseases 0.000 claims 2
- 206010037596 Pyelonephritis Diseases 0.000 claims 2
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 claims 2
- 208000017442 Retinal disease Diseases 0.000 claims 2
- 206010039085 Rhinitis allergic Diseases 0.000 claims 2
- 206010039491 Sarcoma Diseases 0.000 claims 2
- 206010039710 Scleroderma Diseases 0.000 claims 2
- 201000010208 Seminoma Diseases 0.000 claims 2
- 208000021386 Sjogren Syndrome Diseases 0.000 claims 2
- 206010042033 Stevens-Johnson syndrome Diseases 0.000 claims 2
- 231100000168 Stevens-Johnson syndrome Toxicity 0.000 claims 2
- 201000009594 Systemic Scleroderma Diseases 0.000 claims 2
- 206010042953 Systemic sclerosis Diseases 0.000 claims 2
- 208000000491 Tendinopathy Diseases 0.000 claims 2
- 206010043255 Tendonitis Diseases 0.000 claims 2
- 108090000190 Thrombin Proteins 0.000 claims 2
- 208000033781 Thyroid carcinoma Diseases 0.000 claims 2
- 208000024770 Thyroid neoplasm Diseases 0.000 claims 2
- 206010052779 Transplant rejections Diseases 0.000 claims 2
- 206010069363 Traumatic lung injury Diseases 0.000 claims 2
- 208000024780 Urticaria Diseases 0.000 claims 2
- 208000006374 Uterine Cervicitis Diseases 0.000 claims 2
- 206010046851 Uveitis Diseases 0.000 claims 2
- 206010047642 Vitiligo Diseases 0.000 claims 2
- 208000033559 Waldenström macroglobulinemia Diseases 0.000 claims 2
- 230000001154 acute effect Effects 0.000 claims 2
- 206010069351 acute lung injury Diseases 0.000 claims 2
- 208000009956 adenocarcinoma Diseases 0.000 claims 2
- 201000000028 adult respiratory distress syndrome Diseases 0.000 claims 2
- 201000010105 allergic rhinitis Diseases 0.000 claims 2
- 208000004631 alopecia areata Diseases 0.000 claims 2
- 125000004103 aminoalkyl group Chemical group 0.000 claims 2
- 230000036783 anaphylactic response Effects 0.000 claims 2
- 208000003455 anaphylaxis Diseases 0.000 claims 2
- 208000007502 anemia Diseases 0.000 claims 2
- 208000006673 asthma Diseases 0.000 claims 2
- 201000008937 atopic dermatitis Diseases 0.000 claims 2
- 201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 claims 2
- 125000002393 azetidinyl group Chemical group 0.000 claims 2
- 210000000988 bone and bone Anatomy 0.000 claims 2
- 201000004571 bone carcinoma Diseases 0.000 claims 2
- 210000004556 brain Anatomy 0.000 claims 2
- 210000000481 breast Anatomy 0.000 claims 2
- 206010006451 bronchitis Diseases 0.000 claims 2
- 208000000594 bullous pemphigoid Diseases 0.000 claims 2
- 230000001925 catabolic effect Effects 0.000 claims 2
- 230000030833 cell death Effects 0.000 claims 2
- 206010008323 cervicitis Diseases 0.000 claims 2
- 208000003167 cholangitis Diseases 0.000 claims 2
- 201000001352 cholecystitis Diseases 0.000 claims 2
- 208000019069 chronic childhood arthritis Diseases 0.000 claims 2
- 208000025302 chronic primary adrenal insufficiency Diseases 0.000 claims 2
- 210000001072 colon Anatomy 0.000 claims 2
- 201000001981 dermatomyositis Diseases 0.000 claims 2
- 230000001066 destructive effect Effects 0.000 claims 2
- 208000007784 diverticulitis Diseases 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 208000019258 ear infection Diseases 0.000 claims 2
- 210000003981 ectoderm Anatomy 0.000 claims 2
- 206010014599 encephalitis Diseases 0.000 claims 2
- 206010014665 endocarditis Diseases 0.000 claims 2
- 230000002124 endocrine Effects 0.000 claims 2
- 201000011114 epidermolysis bullosa acquisita Diseases 0.000 claims 2
- 210000000918 epididymis Anatomy 0.000 claims 2
- 201000010063 epididymitis Diseases 0.000 claims 2
- 210000003743 erythrocyte Anatomy 0.000 claims 2
- 208000030533 eye disease Diseases 0.000 claims 2
- 208000030941 fetal growth restriction Diseases 0.000 claims 2
- 208000016361 genetic disease Diseases 0.000 claims 2
- 208000005017 glioblastoma Diseases 0.000 claims 2
- 231100000852 glomerular disease Toxicity 0.000 claims 2
- 231100000869 headache Toxicity 0.000 claims 2
- 208000019622 heart disease Diseases 0.000 claims 2
- 208000014951 hematologic disease Diseases 0.000 claims 2
- 208000018706 hematopoietic system disease Diseases 0.000 claims 2
- 208000007475 hemolytic anemia Diseases 0.000 claims 2
- 208000006454 hepatitis Diseases 0.000 claims 2
- 231100000283 hepatitis Toxicity 0.000 claims 2
- 208000025070 hereditary periodic fever syndrome Diseases 0.000 claims 2
- 229940088597 hormone Drugs 0.000 claims 2
- 239000005556 hormone Substances 0.000 claims 2
- 210000004276 hyalin Anatomy 0.000 claims 2
- 230000009610 hypersensitivity Effects 0.000 claims 2
- 208000016036 idiopathic nephrotic syndrome Diseases 0.000 claims 2
- 208000015446 immunoglobulin a vasculitis Diseases 0.000 claims 2
- 208000033065 inborn errors of immunity Diseases 0.000 claims 2
- 201000008319 inclusion body myositis Diseases 0.000 claims 2
- 208000026876 intravascular large B-cell lymphoma Diseases 0.000 claims 2
- 208000002551 irritable bowel syndrome Diseases 0.000 claims 2
- 206010023332 keratitis Diseases 0.000 claims 2
- 201000010666 keratoconjunctivitis Diseases 0.000 claims 2
- 210000003734 kidney Anatomy 0.000 claims 2
- 208000003849 large cell carcinoma Diseases 0.000 claims 2
- 208000032839 leukemia Diseases 0.000 claims 2
- 201000011486 lichen planus Diseases 0.000 claims 2
- 210000004185 liver Anatomy 0.000 claims 2
- 208000019423 liver disease Diseases 0.000 claims 2
- 231100000515 lung injury Toxicity 0.000 claims 2
- 230000001926 lymphatic effect Effects 0.000 claims 2
- 201000000564 macroglobulinemia Diseases 0.000 claims 2
- 208000027202 mammary Paget disease Diseases 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 208000004396 mastitis Diseases 0.000 claims 2
- 230000001404 mediated effect Effects 0.000 claims 2
- 201000001441 melanoma Diseases 0.000 claims 2
- 208000030159 metabolic disease Diseases 0.000 claims 2
- 125000002757 morpholinyl group Chemical group 0.000 claims 2
- 201000000585 muscular atrophy Diseases 0.000 claims 2
- 206010028417 myasthenia gravis Diseases 0.000 claims 2
- 230000009826 neoplastic cell growth Effects 0.000 claims 2
- 208000009928 nephrosis Diseases 0.000 claims 2
- 231100001027 nephrosis Toxicity 0.000 claims 2
- 201000001119 neuropathy Diseases 0.000 claims 2
- 230000007823 neuropathy Effects 0.000 claims 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 2
- 235000020824 obesity Nutrition 0.000 claims 2
- 201000008482 osteoarthritis Diseases 0.000 claims 2
- 210000001672 ovary Anatomy 0.000 claims 2
- 210000000496 pancreas Anatomy 0.000 claims 2
- 201000010198 papillary carcinoma Diseases 0.000 claims 2
- 201000001976 pemphigus vulgaris Diseases 0.000 claims 2
- 208000008494 pericarditis Diseases 0.000 claims 2
- 230000000737 periodic effect Effects 0.000 claims 2
- 201000001245 periodontitis Diseases 0.000 claims 2
- 208000033808 peripheral neuropathy Diseases 0.000 claims 2
- 206010034674 peritonitis Diseases 0.000 claims 2
- 208000001297 phlebitis Diseases 0.000 claims 2
- 125000004193 piperazinyl group Chemical group 0.000 claims 2
- 210000004180 plasmocyte Anatomy 0.000 claims 2
- 208000008423 pleurisy Diseases 0.000 claims 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 2
- 208000028529 primary immunodeficiency disease Diseases 0.000 claims 2
- 201000007094 prostatitis Diseases 0.000 claims 2
- 230000002685 pulmonary effect Effects 0.000 claims 2
- 208000002815 pulmonary hypertension Diseases 0.000 claims 2
- 125000004076 pyridyl group Chemical group 0.000 claims 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 2
- 206010039083 rhinitis Diseases 0.000 claims 2
- 201000000306 sarcoidosis Diseases 0.000 claims 2
- 239000000377 silicon dioxide Substances 0.000 claims 2
- 201000000849 skin cancer Diseases 0.000 claims 2
- 201000008261 skin carcinoma Diseases 0.000 claims 2
- 210000000952 spleen Anatomy 0.000 claims 2
- 208000010110 spontaneous platelet aggregation Diseases 0.000 claims 2
- 210000003802 sputum Anatomy 0.000 claims 2
- 208000024794 sputum Diseases 0.000 claims 2
- 206010041823 squamous cell carcinoma Diseases 0.000 claims 2
- 210000002784 stomach Anatomy 0.000 claims 2
- 208000003265 stomatitis Diseases 0.000 claims 2
- 201000004595 synovitis Diseases 0.000 claims 2
- 201000004415 tendinitis Diseases 0.000 claims 2
- 210000001550 testis Anatomy 0.000 claims 2
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 claims 2
- 125000001412 tetrahydropyranyl group Chemical group 0.000 claims 2
- 125000004568 thiomorpholinyl group Chemical group 0.000 claims 2
- 229960004072 thrombin Drugs 0.000 claims 2
- 201000002510 thyroid cancer Diseases 0.000 claims 2
- 208000013077 thyroid gland carcinoma Diseases 0.000 claims 2
- 208000030901 thyroid gland follicular carcinoma Diseases 0.000 claims 2
- 206010044008 tonsillitis Diseases 0.000 claims 2
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 2
- 210000003932 urinary bladder Anatomy 0.000 claims 2
- 208000002003 vulvitis Diseases 0.000 claims 2
- 125000005940 1,4-dioxanyl group Chemical group 0.000 claims 1
- 208000023328 Basedow disease Diseases 0.000 claims 1
- 206010005149 Blepharitis allergic Diseases 0.000 claims 1
- 206010006811 Bursitis Diseases 0.000 claims 1
- 201000009030 Carcinoma Diseases 0.000 claims 1
- 208000002177 Cataract Diseases 0.000 claims 1
- 206010057254 Connective tissue inflammation Diseases 0.000 claims 1
- 206010012468 Dermatitis herpetiformis Diseases 0.000 claims 1
- 206010058314 Dysplasia Diseases 0.000 claims 1
- 208000001640 Fibromyalgia Diseases 0.000 claims 1
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 claims 1
- 208000003807 Graves Disease Diseases 0.000 claims 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 206010023347 Keratoacanthoma Diseases 0.000 claims 1
- 208000034624 Leukocytoclastic Cutaneous Vasculitis Diseases 0.000 claims 1
- 208000032514 Leukocytoclastic vasculitis Diseases 0.000 claims 1
- 102100022691 NACHT, LRR and PYD domains-containing protein 3 Human genes 0.000 claims 1
- 101710126825 NACHT, LRR and PYD domains-containing protein 3 Proteins 0.000 claims 1
- 206010031149 Osteitis Diseases 0.000 claims 1
- 206010031252 Osteomyelitis Diseases 0.000 claims 1
- 206010034038 Parotitis Diseases 0.000 claims 1
- 208000027086 Pemphigus foliaceus Diseases 0.000 claims 1
- 206010036774 Proctitis Diseases 0.000 claims 1
- 208000007893 Salpingitis Diseases 0.000 claims 1
- 201000002661 Spondylitis Diseases 0.000 claims 1
- 208000024799 Thyroid disease Diseases 0.000 claims 1
- 208000025865 Ulcer Diseases 0.000 claims 1
- 235000018936 Vitellaria paradoxa Nutrition 0.000 claims 1
- 125000003118 aryl group Chemical group 0.000 claims 1
- 208000010217 blepharitis Diseases 0.000 claims 1
- 208000018339 bone inflammation disease Diseases 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 208000016532 chronic granulomatous disease Diseases 0.000 claims 1
- 208000018261 cutaneous leukocytoclastic angiitis Diseases 0.000 claims 1
- 125000000753 cycloalkyl group Chemical group 0.000 claims 1
- 201000003146 cystitis Diseases 0.000 claims 1
- 125000005043 dihydropyranyl group Chemical group O1C(CCC=C1)* 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 208000010227 enterocolitis Diseases 0.000 claims 1
- 210000003979 eosinophil Anatomy 0.000 claims 1
- 230000002327 eosinophilic effect Effects 0.000 claims 1
- 125000002541 furyl group Chemical group 0.000 claims 1
- 210000001035 gastrointestinal tract Anatomy 0.000 claims 1
- 238000005469 granulation Methods 0.000 claims 1
- 230000003179 granulation Effects 0.000 claims 1
- 210000003128 head Anatomy 0.000 claims 1
- 208000014829 head and neck neoplasm Diseases 0.000 claims 1
- 206010020718 hyperplasia Diseases 0.000 claims 1
- 125000002632 imidazolidinyl group Chemical group 0.000 claims 1
- 125000002883 imidazolyl group Chemical group 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 230000000968 intestinal effect Effects 0.000 claims 1
- 125000001786 isothiazolyl group Chemical group 0.000 claims 1
- 125000000842 isoxazolyl group Chemical group 0.000 claims 1
- 210000004561 lacrimal apparatus Anatomy 0.000 claims 1
- 201000003265 lymphadenitis Diseases 0.000 claims 1
- 201000005737 orchitis Diseases 0.000 claims 1
- 125000001715 oxadiazolyl group Chemical group 0.000 claims 1
- 125000000160 oxazolidinyl group Chemical group 0.000 claims 1
- 125000002971 oxazolyl group Chemical group 0.000 claims 1
- 125000003566 oxetanyl group Chemical group 0.000 claims 1
- 206010057056 paraneoplastic pemphigus Diseases 0.000 claims 1
- 210000003681 parotid gland Anatomy 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
- 208000005987 polymyositis Diseases 0.000 claims 1
- 125000003373 pyrazinyl group Chemical group 0.000 claims 1
- 125000003072 pyrazolidinyl group Chemical group 0.000 claims 1
- 125000002098 pyridazinyl group Chemical group 0.000 claims 1
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 1
- 125000000168 pyrrolyl group Chemical group 0.000 claims 1
- 125000003107 substituted aryl group Chemical group 0.000 claims 1
- 125000005346 substituted cycloalkyl group Chemical group 0.000 claims 1
- 125000001984 thiazolidinyl group Chemical group 0.000 claims 1
- 125000000335 thiazolyl group Chemical group 0.000 claims 1
- 125000001544 thienyl group Chemical group 0.000 claims 1
- 208000021510 thyroid gland disease Diseases 0.000 claims 1
- 206010043778 thyroiditis Diseases 0.000 claims 1
- 125000001425 triazolyl group Chemical group 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN158/CHE/2014 | 2014-01-13 | ||
| IN158CH2014 | 2014-01-13 | ||
| IN3000CH2014 | 2014-06-20 | ||
| IN3000/CHE/2014 | 2014-06-20 | ||
| PCT/IB2015/050217 WO2015104688A1 (en) | 2014-01-13 | 2015-01-12 | Bicyclic heterocyclyl derivatives as irak4 inhibitors |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019019229A Division JP6750053B2 (ja) | 2014-01-13 | 2019-02-06 | Ｉｒａｋ４阻害剤としての二環式ヘテロシクリル誘導体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017502088A JP2017502088A (ja) | 2017-01-19 |
| JP2017502088A5 true JP2017502088A5 (enExample) | 2018-02-15 |
| JP6479850B2 JP6479850B2 (ja) | 2019-03-06 |
Family
ID=53523587
Family Applications (7)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016563278A Active JP6479850B2 (ja) | 2014-01-13 | 2015-01-12 | Ｉｒａｋ４阻害剤としての二環式ヘテロシクリル誘導体 |
| JP2019019229A Active JP6750053B2 (ja) | 2014-01-13 | 2019-02-06 | Ｉｒａｋ４阻害剤としての二環式ヘテロシクリル誘導体 |
| JP2020109507A Active JP6977111B2 (ja) | 2014-01-13 | 2020-06-25 | Ｉｒａｋ４阻害剤としての二環式ヘテロシクリル誘導体 |
| JP2021183016A Active JP7262553B2 (ja) | 2014-01-13 | 2021-11-10 | Ｉｒａｋ４阻害剤としての二環式ヘテロシクリル誘導体 |
| JP2023063800A Active JP7601937B2 (ja) | 2014-01-13 | 2023-04-11 | Ｉｒａｋ４阻害剤としての二環式ヘテロシクリル誘導体 |
| JP2024211949A Active JP7775430B2 (ja) | 2014-01-13 | 2024-12-05 | Ｉｒａｋ４阻害剤としての二環式ヘテロシクリル誘導体 |
| JP2025191819A Pending JP2026027431A (ja) | 2014-01-13 | 2025-11-12 | Ｉｒａｋ４阻害剤としての二環式ヘテロシクリル誘導体 |
Family Applications After (6)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019019229A Active JP6750053B2 (ja) | 2014-01-13 | 2019-02-06 | Ｉｒａｋ４阻害剤としての二環式ヘテロシクリル誘導体 |
| JP2020109507A Active JP6977111B2 (ja) | 2014-01-13 | 2020-06-25 | Ｉｒａｋ４阻害剤としての二環式ヘテロシクリル誘導体 |
| JP2021183016A Active JP7262553B2 (ja) | 2014-01-13 | 2021-11-10 | Ｉｒａｋ４阻害剤としての二環式ヘテロシクリル誘導体 |
| JP2023063800A Active JP7601937B2 (ja) | 2014-01-13 | 2023-04-11 | Ｉｒａｋ４阻害剤としての二環式ヘテロシクリル誘導体 |
| JP2024211949A Active JP7775430B2 (ja) | 2014-01-13 | 2024-12-05 | Ｉｒａｋ４阻害剤としての二環式ヘテロシクリル誘導体 |
| JP2025191819A Pending JP2026027431A (ja) | 2014-01-13 | 2025-11-12 | Ｉｒａｋ４阻害剤としての二環式ヘテロシクリル誘導体 |
Country Status (31)
| Country | Link |
|---|---|
| US (8) | US9732095B2 (enExample) |
| EP (4) | EP4353324A3 (enExample) |
| JP (7) | JP6479850B2 (enExample) |
| KR (4) | KR102574390B1 (enExample) |
| CN (2) | CN106456619B (enExample) |
| AU (6) | AU2015205374B2 (enExample) |
| BR (1) | BR112016016158B1 (enExample) |
| CA (1) | CA2935887A1 (enExample) |
| CU (1) | CU24389B1 (enExample) |
| CY (2) | CY1121433T1 (enExample) |
| DK (3) | DK3805233T3 (enExample) |
| EA (2) | EA038748B1 (enExample) |
| ES (3) | ES2846678T3 (enExample) |
| FI (1) | FI3805233T3 (enExample) |
| HR (3) | HRP20240489T1 (enExample) |
| HU (3) | HUE041926T2 (enExample) |
| IL (7) | IL311677B2 (enExample) |
| LT (3) | LT3466955T (enExample) |
| MX (1) | MX359909B (enExample) |
| MY (1) | MY197116A (enExample) |
| NZ (2) | NZ760657A (enExample) |
| PH (2) | PH12016501344A1 (enExample) |
| PL (3) | PL3466955T3 (enExample) |
| PT (3) | PT3805233T (enExample) |
| RS (3) | RS58024B1 (enExample) |
| SG (2) | SG11201605486WA (enExample) |
| SI (3) | SI3466955T1 (enExample) |
| SM (3) | SMT202400142T1 (enExample) |
| TR (1) | TR201815683T4 (enExample) |
| WO (1) | WO2015104688A1 (enExample) |
| ZA (4) | ZA202007275B (enExample) |
Families Citing this family (66)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201311891D0 (en) | 2013-07-03 | 2013-08-14 | Glaxosmithkline Ip Dev Ltd | Novel compound |
| GB201311888D0 (en) | 2013-07-03 | 2013-08-14 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
| BR112016015983A2 (pt) | 2014-01-10 | 2017-08-08 | Aurigene Discovery Tech Ltd | Compostos de indazol como inibidores de irak4, seus usos, e composição farmacêutica |
| SMT202400142T1 (it) * | 2014-01-13 | 2024-05-14 | Aurigene Oncology Ltd | Enantiomeri (r) e (s) di n-(5-(3-idrossipirrolidin-1-il)-2-morfolinoossazolo[4,5-b]piridin-6-il)-2-(2-metilpiridin-4-il)ossazolo-carbossammide in qualità di inibitori di irak4 per il trattamento di un cancro |
| US20180228907A1 (en) | 2014-04-14 | 2018-08-16 | Arvinas, Inc. | Cereblon ligands and bifunctional compounds comprising the same |
| CN108024971A (zh) * | 2015-07-15 | 2018-05-11 | 奥列基因发现技术有限公司 | 作为irak-4抑制剂的取代的氮杂化合物 |
| ES2811136T3 (es) | 2015-08-04 | 2021-03-10 | Rigel Pharmaceuticals Inc | Compuestos de benzazol y métodos para obtener y usar los compuestos |
| JP6947743B2 (ja) | 2016-03-03 | 2021-10-13 | バイエル・ファルマ・アクティエンゲゼルシャフト | 新規な２−置換インダゾール、その製造方法、それを含有する医薬製剤、および薬物を製造するためのその使用 |
| TWI733982B (zh) | 2017-02-16 | 2021-07-21 | 美商基利科學股份有限公司 | 吡咯并[1,2-b]嗒衍生物 |
| CN120267671A (zh) | 2017-03-31 | 2025-07-08 | 奥锐金肿瘤有限公司 | 用于治疗血液病的化合物和组合物 |
| JP7366031B2 (ja) | 2017-09-22 | 2023-10-20 | カイメラ セラピューティクス， インコーポレイテッド | タンパク質分解剤およびそれらの使用 |
| WO2019060693A1 (en) | 2017-09-22 | 2019-03-28 | Kymera Therapeutics, Inc. | CRBN LIGANDS AND USES THEREOF |
| MX2020003666A (es) * | 2017-10-31 | 2020-08-03 | Curis Inc | Compuestos y composiciones para el tratamiento de trastornos hematologicos. |
| US11065231B2 (en) | 2017-11-17 | 2021-07-20 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of interleukin-1 receptor- associated kinase 4 polypeptides |
| WO2019111218A1 (en) | 2017-12-08 | 2019-06-13 | Cadila Healthcare Limited | Novel heterocyclic compounds as irak4 inhibitors |
| IL315310A (en) | 2017-12-26 | 2024-10-01 | Kymera Therapeutics Inc | Irak degraders and uses thereof |
| EP3737666A4 (en) | 2018-01-12 | 2022-01-05 | Kymera Therapeutics, Inc. | PROTEIN DEGRADATION AGENTS AND ASSOCIATED USES |
| US11512080B2 (en) | 2018-01-12 | 2022-11-29 | Kymera Therapeutics, Inc. | CRBN ligands and uses thereof |
| EP3305786A3 (de) | 2018-01-22 | 2018-07-25 | Bayer CropScience Aktiengesellschaft | Kondensierte bicyclische heterocyclen-derivate als schädlingsbekämpfungsmittel |
| CA3090275A1 (en) | 2018-02-14 | 2019-08-22 | Dana-Farber Cancer Institute, Inc. | Irak degraders and uses thereof |
| EP3817822A4 (en) | 2018-07-06 | 2022-07-27 | Kymera Therapeutics, Inc. | PROTEIN DEGRADANTS AND USES THEREOF |
| WO2020010177A1 (en) | 2018-07-06 | 2020-01-09 | Kymera Therapeutics, Inc. | Tricyclic crbn ligands and uses thereof |
| TWI721483B (zh) | 2018-07-13 | 2021-03-11 | 美商基利科學股份有限公司 | 吡咯并[1,2-b]嗒𠯤衍生物 |
| CA3224985C (en) | 2018-07-31 | 2025-11-18 | Loxo Oncology, Inc. | SPRAY-DRIED DISPERSIONS, FORMULATIONS AND POLYMORPHIES OF (S)-5-AMINO-3-(4-((5-FLUORO-2-METHOXYBENZAMIDO)METHYL)PHENYL)(1,1,1-TRIFLUOROPROPANE-2-YL)-1H-PYRAZOLE-4-CARBOXAMIDE |
| JP7623943B2 (ja) | 2018-11-30 | 2025-01-29 | カイメラ セラピューティクス， インコーポレイテッド | Ｉｒａｋ分解剤およびそれらの使用 |
| US20220089592A1 (en) * | 2019-01-18 | 2022-03-24 | Biogen Ma Inc. | Imidazo[1,2-a]pyridinyl derivatives as irak4 inhibitors |
| BR112021026517A2 (pt) | 2019-06-28 | 2022-05-10 | Kymera Therapeutics Inc | Degradadores de irak e usos dos mesmos |
| WO2021004533A1 (zh) * | 2019-07-10 | 2021-01-14 | 南京明德新药研发有限公司 | 作为irak4和btk多靶点抑制剂的噁唑类化合物 |
| WO2021011868A1 (en) | 2019-07-17 | 2021-01-21 | Kymera Therapeutics, Inc. | Irak degraders and uses thereof |
| ES2961950T3 (es) | 2019-07-18 | 2024-03-14 | Bristol Myers Squibb Co | Compuestos heteroarílicos tricíclicos útiles como inhibidores de IRAK4 |
| EP3999512B1 (en) | 2019-07-18 | 2023-08-23 | Bristol-Myers Squibb Company | Pyrazolo[3,4-d]pyrrolo[1,2-b]pyridazinyl compounds useful as irak4 inhibitors |
| JP7573596B2 (ja) * | 2019-07-23 | 2024-10-25 | ブリストル－マイヤーズ スクイブ カンパニー | Ｉｒａｋ４阻害剤として有用なチエノピリジニルおよびチアゾロピリジニル化合物 |
| JP7682154B2 (ja) | 2019-08-06 | 2025-05-23 | ブリストル－マイヤーズ スクイブ カンパニー | Ｉｒａｋ４阻害剤として有用な二環ヘテロ環式化合物 |
| EP3772513A1 (en) * | 2019-08-09 | 2021-02-10 | C.N.C.C.S. S.c.a.r.l. Collezione Nazionale Dei Composti Chimici e Centro Screening | Shp2 inhibitors |
| EP4013758B1 (en) | 2019-08-13 | 2025-12-24 | Bristol-Myers Squibb Company | Bicyclic heteroaryl compounds useful as irak4 inhibitors |
| AU2020360000B2 (en) | 2019-10-02 | 2023-04-20 | Kainos Medicine, Inc. | N-(1H-imidazol-2-yl)benzamide compound and pharmaceutical composition comprising the same as active ingredient |
| EP4072591A4 (en) | 2019-12-10 | 2024-06-05 | Kymera Therapeutics, Inc. | IRAQ DEGRADER AND USES THEREOF |
| WO2021127283A2 (en) | 2019-12-17 | 2021-06-24 | Kymera Therapeutics, Inc. | Irak degraders and uses thereof |
| JP2023509366A (ja) | 2019-12-17 | 2023-03-08 | カイメラ セラピューティクス， インコーポレイテッド | Ｉｒａｋ分解剤およびそれらの使用 |
| US12391702B2 (en) | 2020-02-03 | 2025-08-19 | Bristol-Myers Squibb Company | Benzo[5,6][1,4]dioxino[2,3-b]pyridine compounds useful as IRAK4 inhibitors |
| CA3177852A1 (en) | 2020-04-04 | 2021-10-07 | Pfizer Inc. | Methods of treating coronavirus disease 2019 |
| WO2021204589A1 (en) | 2020-04-07 | 2021-10-14 | Bayer Aktiengesellschaft | Substituted thiazolopyridines, salts thereof and their use as herbicidally active substances |
| WO2021222366A1 (en) * | 2020-04-28 | 2021-11-04 | Kymera Therapeutics, Inc. | Irak inhibitors and uses thereof |
| TW202210483A (zh) | 2020-06-03 | 2022-03-16 | 美商凱麥拉醫療公司 | Irak降解劑之結晶型 |
| KR20230048358A (ko) * | 2020-08-03 | 2023-04-11 | 쿠리스 인코퍼레이션 | 질환 및 장애를 치료하기 위한 조성물 및 방법 |
| EP4237423B1 (en) | 2020-11-02 | 2024-12-11 | Boehringer Ingelheim International GmbH | Substituted 1h-pyrazolo[4,3-c]pyridines and derivatives as egfr inhibitors |
| WO2022108996A1 (en) * | 2020-11-18 | 2022-05-27 | Curis, Inc. | Methods of treating diseases and disorders |
| EP4269409A4 (en) * | 2020-12-25 | 2024-12-11 | Medshine Discovery Inc. | AMIDE-OXAZOLE COMPOUND |
| WO2022147465A1 (en) | 2020-12-30 | 2022-07-07 | Kymera Therapeutics, Inc. | Irak degraders and uses thereof |
| TW202245788A (zh) | 2021-02-15 | 2022-12-01 | 美商凱麥拉醫療公司 | Irak4降解劑及其用途 |
| CN116867494A (zh) | 2021-02-15 | 2023-10-10 | 凯麦拉医疗公司 | Irak4降解剂和其用途 |
| US12178821B2 (en) | 2021-04-08 | 2024-12-31 | Curis, Inc. | Combination therapies for the treatment of cancer |
| AU2022271290A1 (en) | 2021-05-07 | 2023-11-23 | Kymera Therapeutics, Inc. | Cdk2 degraders and uses thereof |
| TW202328150A (zh) | 2021-09-07 | 2023-07-16 | 德商拜耳廠股份有限公司 | 經取代之噻唑并吡啶、其鹽及其作為除草活性物質之用途 |
| TW202328151A (zh) | 2021-09-07 | 2023-07-16 | 德商拜耳廠股份有限公司 | 經取代之2,3-二氫[1,3]噻唑并[4,5-b]吡啶、其鹽及其作為除草活性物質之用途 |
| EP4422635A4 (en) | 2021-10-29 | 2025-11-26 | Kymera Therapeutics Inc | IRAQ4 DEGRADATION AGENTS AND THEIR SYNTHESIS |
| TWI890016B (zh) | 2021-12-23 | 2025-07-11 | 大陸商杭州多域生物技術有限公司 | 一種五員并六員化合物、製備方法、藥物組成物和應用 |
| TW202330546A (zh) * | 2021-12-31 | 2023-08-01 | 香港商愛科諾生物醫藥(香港)有限公司 | 具有irak4抑制活性的化合物，包含其的藥物組合物，及其應用 |
| IL314437A (en) | 2022-01-31 | 2024-09-01 | Kymera Therapeutics Inc | IRAK joints and their uses |
| US12384775B2 (en) | 2022-03-23 | 2025-08-12 | Rigel Pharmaceuticals, Inc. | Pyrimid-2-yl-pyrazole compounds as IRAK inhibitors |
| JP2025534698A (ja) * | 2022-10-13 | 2025-10-17 | カイメラ セラピューティクス， インコーポレイテッド | Ｉｒａｋ４デグレーダーの塩の形態 |
| WO2024092011A1 (en) * | 2022-10-25 | 2024-05-02 | Kymera Therapeutics, Inc. | Irak degraders and uses thereof |
| WO2025130871A1 (zh) * | 2023-12-20 | 2025-06-26 | 爱科诺生物医药(香港)有限公司 | 具有irak4和flt3蛋白双重降解活性的化合物，包含其的药物组合物，及其应用 |
| WO2025208000A1 (en) * | 2024-03-29 | 2025-10-02 | Curis, Inc. | Methods of treating cancer in patients with altered protein expression |
| WO2026005536A1 (ko) * | 2024-06-28 | 2026-01-02 | 주식회사 대웅제약 | 신규한 화합물, 및 이를 포함하는 암 또는 자가 면역 질환의 예방 또는 치료용 약학적 조성물 |
| CN119119080A (zh) * | 2024-09-06 | 2024-12-13 | 上海信诺维生物医药有限公司 | 一种irak4的蛋白降解剂 |
Family Cites Families (82)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2102367T3 (es) | 1990-05-18 | 1997-08-01 | Hoechst Ag | Amidas de acidos isoxazol-4-carboxilicos y amidas de acidos hidroxialquiliden-cianoaceticos, medicamentos que contienen estos compuestos y su utilizacion. |
| DE10023486C1 (de) | 2000-05-09 | 2002-03-14 | Schering Ag | Ortho substituierte Anthranilsäureamide und deren Verwendung als Arzneimittel |
| US6878714B2 (en) | 2001-01-12 | 2005-04-12 | Amgen Inc. | Substituted alkylamine derivatives and methods of use |
| US20030134836A1 (en) | 2001-01-12 | 2003-07-17 | Amgen Inc. | Substituted arylamine derivatives and methods of use |
| WO2004063151A2 (en) * | 2003-01-03 | 2004-07-29 | Bristol-Myers Squibb Company | Novel tyrosine kinase inhibitors |
| US7651469B2 (en) | 2003-04-25 | 2010-01-26 | Cook Incorporated | Low friction coated marked wire guide for over the wire insertion of a catheter |
| ES2350837T3 (es) | 2003-05-01 | 2011-01-27 | Bristol-Myers Squibb Company | Compuestos de pirazol-amida sustituidos con arilo útiles como inhibidores de quinasas. |
| ATE556067T1 (de) | 2003-05-20 | 2012-05-15 | Ajinomoto Kk | Modulatoren des vanilloid rezeptors |
| EP1628661A2 (en) | 2003-06-05 | 2006-03-01 | Vertex Pharmaceuticals Incorporated | Modulators of vr1 receptor |
| EP1493795A1 (de) | 2003-07-04 | 2005-01-05 | Collano AG | Klebstoffzusammensetzung |
| WO2005032493A2 (en) | 2003-10-07 | 2005-04-14 | Renovis, Inc. | Amide compounds as ion channel ligands and uses thereof |
| MY145634A (en) * | 2003-12-29 | 2012-03-15 | Bristol Myers Squibb Co | Pyrrolotriazine compounds as kinase inhibitors |
| MXPA06012104A (es) | 2004-04-22 | 2007-01-25 | Bayer Cropscience Lp | Metodo y composicion para controlar malas hierbas. |
| US7906533B2 (en) | 2004-11-03 | 2011-03-15 | Bayer Schering Pharma Ag | Nicotinamide pyridinureas as vascular endothelial growth factor (VEGF) receptor kinase inhibitors |
| EP1655297A1 (en) | 2004-11-03 | 2006-05-10 | Schering Aktiengesellschaft | Nicotinamide pyridinureas as vascular endothelial growth factor (VEGF) receptor kinase inhibitors |
| TW200628159A (en) | 2004-11-10 | 2006-08-16 | Synta Pharmaceuticals Corp | IL-12 modulatory compounds |
| US7902356B2 (en) | 2004-12-17 | 2011-03-08 | Eli Lilly And Company | Thiazolopyridinone derivates as MCH receptor antagonists |
| CN101072775A (zh) | 2004-12-17 | 2007-11-14 | 伊莱利利公司 | 新的mch受体拮抗剂 |
| EP1674467A1 (en) | 2004-12-22 | 2006-06-28 | 4Sc Ag | 2,5- and 2,6-disubstituted benzazole derivatives useful as protein kinase inhibitors |
| WO2007058626A1 (en) | 2005-11-16 | 2007-05-24 | S*Bio Pte Ltd | Indazole compounds |
| AU2007215247B2 (en) | 2006-02-10 | 2012-12-13 | Transtech Pharma, Llc | Benzazole derivatives, compositions, and methods of use as Aurora kinase inhibitors |
| GB0606429D0 (en) | 2006-03-30 | 2006-05-10 | Novartis Ag | Organic compounds |
| WO2007117465A2 (en) | 2006-03-31 | 2007-10-18 | Abbott Laboratories | Indazole compounds |
| WO2007121154A2 (en) | 2006-04-11 | 2007-10-25 | Janssen Pharmaceutica, N.V. | Substituted benzothiazole kinase inhibitors |
| RU2459821C2 (ru) * | 2006-09-07 | 2012-08-27 | Байоджен Айдек Ма Инк. | Модуляторы киназы, ассоциированной с рецептором интерлейкина-1 |
| AU2007292924A1 (en) * | 2006-09-07 | 2008-03-13 | Biogen Idec Ma Inc. | IRAK modulators for treating an inflammatory condition, cell proliferative disorder, immune disorder |
| WO2008061109A2 (en) | 2006-11-15 | 2008-05-22 | Forest Laboratories Holdings Limited | Indazole derivatives useful as melanin concentrating receptor ligands |
| WO2008073825A1 (en) | 2006-12-08 | 2008-06-19 | Exelixis, Inc. | Lxr and fxr modulators |
| JP4785881B2 (ja) | 2007-02-27 | 2011-10-05 | 大塚製薬株式会社 | 医薬 |
| AR066958A1 (es) | 2007-06-14 | 2009-09-23 | Schering Corp | Imidazopirazinas como inhibidores de proteina quinasa |
| US20090069288A1 (en) | 2007-07-16 | 2009-03-12 | Breinlinger Eric C | Novel therapeutic compounds |
| CA2690619A1 (en) | 2007-07-16 | 2009-01-22 | Abbott Laboratories | Indazoles, benzisoxazoles and benzisothiazoles as inhibitors of protein kinases |
| BRPI0814975A2 (pt) | 2007-08-08 | 2015-02-03 | Merck Serono Sa | Derivados de 6-amino-pirimidina-4-carboxamida e compostos relacionados que se ligam ao receptor de 1-fosfato de esfingosina (s1p) para o tratamento de esclerose múltipla |
| NZ587039A (en) | 2008-02-13 | 2013-01-25 | Gilead Connecticut Inc | 6-aryl-imidazo[1, 2-a]pyrazine derivatives, method of making, and method of use thereof |
| EP2311842A3 (en) | 2008-06-24 | 2011-07-13 | Takeda Pharmaceutical Company Limited | PI3K/M TOR inhibitors |
| CA2743609A1 (en) | 2008-11-19 | 2010-05-27 | Schering Corporation | Inhibitors of diacylglycerol acyltransferase |
| EP2379564A1 (en) * | 2008-12-19 | 2011-10-26 | Schering Corporation | Bicyclic heterocyclic derivatives and methods of use thereof |
| EP2393781B1 (en) | 2008-12-23 | 2014-03-12 | F. Hoffmann-La Roche AG | Dihydropyridone ureas as p2x7 modulators |
| EP2440058A4 (en) | 2009-06-12 | 2012-11-21 | Dana Farber Cancer Inst Inc | MELTED HETEROCYCLIC COMPOUNDS AND APPLICATIONS THEREOF |
| BR112012003661A2 (pt) | 2009-08-19 | 2017-04-25 | Ambit Biosciences Corp | "compostos de biarila e métodos de uso dos mesmos." |
| JP2012254939A (ja) | 2009-10-07 | 2012-12-27 | Astellas Pharma Inc | オキサゾール化合物 |
| JP5819305B2 (ja) | 2009-10-13 | 2015-11-24 | リガンド・ファーマシューティカルズ・インコーポレイテッド | 造血成長因子模倣小分子化合物およびそれらの使用 |
| JP2013525370A (ja) | 2010-04-22 | 2013-06-20 | ヤンセン ファーマシューティカ エヌ．ベー． | ケトヘキソキナーゼ阻害剤として有用なインダゾール化合物 |
| EP2563358A4 (en) | 2010-04-30 | 2013-09-25 | Merck Sharp & Dohme | INHIBITORS OF PHOSPHOINOSITIDE-DEPENDENT KINASE 1 (PDK1) |
| HRP20171176T1 (hr) | 2010-06-24 | 2017-10-06 | Chemocentryx, Inc. | C5ar antagonisti |
| CN102985426B (zh) | 2010-07-13 | 2015-10-07 | 弗·哈夫曼-拉罗切有限公司 | 作为irak4调节剂的吡唑并[1,5a]嘧啶和噻吩并[3,2b]嘧啶衍生物 |
| HUE037860T2 (hu) | 2010-11-19 | 2018-09-28 | Ligand Pharm Inc | Heterociklusos aminok és alkalmazásuk |
| WO2012084704A1 (en) | 2010-12-20 | 2012-06-28 | Merck Serono S.A. | Indazolyl triazole derivatives as irak inhibitors |
| WO2012142125A2 (en) | 2011-04-12 | 2012-10-18 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Plasmodial surface anion channel inhibitors for the treatment or prevention of malaria |
| WO2013042137A1 (en) * | 2011-09-19 | 2013-03-28 | Aurigene Discovery Technologies Limited | Bicyclic heterocycles as irak4 inhibitors |
| MY167575A (en) | 2011-10-14 | 2018-09-20 | Ambit Biosciences Corp | Heterocyclic compounds and use thereof as modulators of type iii receptor tyrosine kinases |
| RU2014120166A (ru) | 2011-10-20 | 2015-11-27 | ГЛЭКСОСМИТКЛАЙН ЭлЭлСи | Замещенные бициклические аза-гетероциклы и их аналоги в качестве модуляторов сиртуина |
| US9221809B2 (en) * | 2011-10-31 | 2015-12-29 | Merck Sharp & Dohme Corp. | Aminopyrimidinones as interleukin receptor-associated kinase inhibitors |
| GB201119401D0 (en) | 2011-11-10 | 2011-12-21 | Ucb Pharma Sa | Therapeutic agents |
| KR101385603B1 (ko) | 2012-05-17 | 2014-04-21 | 한국원자력의학원 | 벤조티아졸 유도체 및 암 치료를 위한 그의 용도 |
| WO2014003483A1 (en) | 2012-06-29 | 2014-01-03 | Hanmi Pharm. Co., Ltd. | Fused pyrimidine derivatives having inhibitory activity on fms kinases |
| HK1210696A1 (en) | 2012-07-11 | 2016-05-06 | Nimbus Iris, Inc. | Irak inhibitors and uses thereof |
| JP6372666B2 (ja) | 2012-11-03 | 2018-08-15 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | サイトメガロウイルスの阻害剤 |
| US9168257B2 (en) | 2013-05-22 | 2015-10-27 | Children's Hospital Medical Center | Combination therapy for MDS |
| TWI652014B (zh) | 2013-09-13 | 2019-03-01 | 美商艾佛艾姆希公司 | 雜環取代之雙環唑殺蟲劑 |
| TWI667233B (zh) | 2013-12-19 | 2019-08-01 | 德商拜耳製藥公司 | 新穎吲唑羧醯胺，其製備方法、含彼等之醫藥製劑及其製造醫藥之用途 |
| BR112016015983A2 (pt) | 2014-01-10 | 2017-08-08 | Aurigene Discovery Tech Ltd | Compostos de indazol como inibidores de irak4, seus usos, e composição farmacêutica |
| SMT202400142T1 (it) | 2014-01-13 | 2024-05-14 | Aurigene Oncology Ltd | Enantiomeri (r) e (s) di n-(5-(3-idrossipirrolidin-1-il)-2-morfolinoossazolo[4,5-b]piridin-6-il)-2-(2-metilpiridin-4-il)ossazolo-carbossammide in qualità di inibitori di irak4 per il trattamento di un cancro |
| JP6532474B2 (ja) | 2014-02-06 | 2019-06-19 | アッヴィ・インコーポレイテッド | ６−ヘテロアリールオキシ−および６−アリールオキシ−キノリン−２−カルボキシアミドならびにその使用 |
| KR20170016500A (ko) | 2014-06-20 | 2017-02-13 | 오리진 디스커버리 테크놀로지스 리미티드 | Irak4 저해제로서의 치환된 인다졸 화합물 |
| JO3705B1 (ar) | 2014-11-26 | 2021-01-31 | Bayer Pharma AG | إندازولات مستبدلة جديدة، عمليات لتحضيرها، مستحضرات دوائية تحتوي عليها واستخدامها في إنتاج أدوية |
| TW201701879A (zh) | 2015-04-30 | 2017-01-16 | 拜耳製藥公司 | Ｉｒａｋ４抑制劑組合 |
| AU2016293441A1 (en) | 2015-07-15 | 2018-02-01 | Aurigene Discovery Technologies Limited | Indazole and azaindazole compounds as IRAK-4 inhibitors |
| CN108024971A (zh) | 2015-07-15 | 2018-05-11 | 奥列基因发现技术有限公司 | 作为irak-4抑制剂的取代的氮杂化合物 |
| ES2811136T3 (es) | 2015-08-04 | 2021-03-10 | Rigel Pharmaceuticals Inc | Compuestos de benzazol y métodos para obtener y usar los compuestos |
| US20170035881A1 (en) | 2015-10-19 | 2017-02-09 | Acerta Pharma B.V. | Therapeutic Combinations of an IRAK4 Inhibitor and a BTK Inhibitor |
| US20210292843A1 (en) | 2016-10-28 | 2021-09-23 | Children's Hospital Medical Center | Treatment of diseases associated with activated irak |
| CN120267671A (zh) | 2017-03-31 | 2025-07-08 | 奥锐金肿瘤有限公司 | 用于治疗血液病的化合物和组合物 |
| MX2020003666A (es) | 2017-10-31 | 2020-08-03 | Curis Inc | Compuestos y composiciones para el tratamiento de trastornos hematologicos. |
| JP7623943B2 (ja) | 2018-11-30 | 2025-01-29 | カイメラ セラピューティクス， インコーポレイテッド | Ｉｒａｋ分解剤およびそれらの使用 |
| BR112021026517A2 (pt) | 2019-06-28 | 2022-05-10 | Kymera Therapeutics Inc | Degradadores de irak e usos dos mesmos |
| KR20230048358A (ko) | 2020-08-03 | 2023-04-11 | 쿠리스 인코퍼레이션 | 질환 및 장애를 치료하기 위한 조성물 및 방법 |
| WO2022108996A1 (en) | 2020-11-18 | 2022-05-27 | Curis, Inc. | Methods of treating diseases and disorders |
| US12178821B2 (en) | 2021-04-08 | 2024-12-31 | Curis, Inc. | Combination therapies for the treatment of cancer |
| IL316793A (en) | 2022-05-11 | 2025-01-01 | Curis Inc | Treating diseases and disorders with compounds that modify IRAK4 |
| WO2024249837A1 (en) | 2023-06-01 | 2024-12-05 | Curis, Inc. | Methods of treating cancer in bcl2 inhibitor naive subjects |
| CN121398817A (zh) | 2023-06-01 | 2026-01-23 | 柯里斯公司 | 治疗具有先前免疫检查点抑制剂暴露的受试者的癌症的方法 |
-
2015
- 2015-01-12 SM SM20240142T patent/SMT202400142T1/it unknown
- 2015-01-12 DK DK20211096.1T patent/DK3805233T3/da active
- 2015-01-12 IL IL311677A patent/IL311677B2/en unknown
- 2015-01-12 HR HRP20240489TT patent/HRP20240489T1/hr unknown
- 2015-01-12 HU HUE15735499A patent/HUE041926T2/hu unknown
- 2015-01-12 CA CA2935887A patent/CA2935887A1/en active Pending
- 2015-01-12 SG SG11201605486WA patent/SG11201605486WA/en unknown
- 2015-01-12 KR KR1020227014075A patent/KR102574390B1/ko active Active
- 2015-01-12 SM SM20180680T patent/SMT201800680T1/it unknown
- 2015-01-12 DK DK18190333.7T patent/DK3466955T3/da active
- 2015-01-12 ES ES18190333T patent/ES2846678T3/es active Active
- 2015-01-12 HU HUE20211096A patent/HUE066261T2/hu unknown
- 2015-01-12 LT LTEP18190333.7T patent/LT3466955T/lt unknown
- 2015-01-12 SM SM20210063T patent/SMT202100063T1/it unknown
- 2015-01-12 KR KR1020257009008A patent/KR20250049413A/ko active Pending
- 2015-01-12 EP EP23214923.7A patent/EP4353324A3/en active Pending
- 2015-01-12 IL IL284952A patent/IL284952B/en unknown
- 2015-01-12 TR TR2018/15683T patent/TR201815683T4/tr unknown
- 2015-01-12 NZ NZ760657A patent/NZ760657A/en unknown
- 2015-01-12 IL IL294895A patent/IL294895B2/en unknown
- 2015-01-12 HU HUE18190333A patent/HUE052252T2/hu unknown
- 2015-01-12 HR HRP20181795TT patent/HRP20181795T1/hr unknown
- 2015-01-12 NZ NZ722019A patent/NZ722019A/en unknown
- 2015-01-12 MX MX2016009013A patent/MX359909B/es active IP Right Grant
- 2015-01-12 EP EP18190333.7A patent/EP3466955B1/en active Active
- 2015-01-12 ES ES15735499.4T patent/ES2692852T3/es active Active
- 2015-01-12 IL IL317922A patent/IL317922A/en unknown
- 2015-01-12 RS RS20181355A patent/RS58024B1/sr unknown
- 2015-01-12 EA EA201891917A patent/EA038748B1/ru unknown
- 2015-01-12 PT PT202110961T patent/PT3805233T/pt unknown
- 2015-01-12 IL IL302878A patent/IL302878B2/en unknown
- 2015-01-12 BR BR112016016158-0A patent/BR112016016158B1/pt active IP Right Grant
- 2015-01-12 SG SG10201811204RA patent/SG10201811204RA/en unknown
- 2015-01-12 EP EP15735499.4A patent/EP3094329B1/en active Active
- 2015-01-12 CN CN201580013752.4A patent/CN106456619B/zh active Active
- 2015-01-12 AU AU2015205374A patent/AU2015205374B2/en active Active
- 2015-01-12 DK DK15735499.4T patent/DK3094329T3/en active
- 2015-01-12 KR KR1020237029626A patent/KR102785576B1/ko active Active
- 2015-01-12 PL PL18190333T patent/PL3466955T3/pl unknown
- 2015-01-12 EP EP20211096.1A patent/EP3805233B1/en active Active
- 2015-01-12 RS RS20210039A patent/RS61448B1/sr unknown
- 2015-01-12 LT LTEP20211096.1T patent/LT3805233T/lt unknown
- 2015-01-12 FI FIEP20211096.1T patent/FI3805233T3/fi active
- 2015-01-12 PL PL15735499T patent/PL3094329T3/pl unknown
- 2015-01-12 KR KR1020167021713A patent/KR102392684B1/ko active Active
- 2015-01-12 SI SI201531483T patent/SI3466955T1/sl unknown
- 2015-01-12 LT LTEP15735499.4T patent/LT3094329T/lt unknown
- 2015-01-12 SI SI201530477T patent/SI3094329T1/sl unknown
- 2015-01-12 ES ES20211096T patent/ES2975436T3/es active Active
- 2015-01-12 CN CN202010147212.8A patent/CN111362966B/zh active Active
- 2015-01-12 WO PCT/IB2015/050217 patent/WO2015104688A1/en not_active Ceased
- 2015-01-12 CU CU2016000111A patent/CU24389B1/es unknown
- 2015-01-12 PT PT15735499T patent/PT3094329T/pt unknown
- 2015-01-12 PT PT181903337T patent/PT3466955T/pt unknown
- 2015-01-12 PL PL20211096.1T patent/PL3805233T3/pl unknown
- 2015-01-12 SI SI201532008T patent/SI3805233T1/sl unknown
- 2015-01-12 US US15/111,000 patent/US9732095B2/en active Active
- 2015-01-12 RS RS20240415A patent/RS65437B1/sr unknown
- 2015-01-12 EA EA201691428A patent/EA031913B1/ru unknown
- 2015-01-12 MY MYPI2021007377A patent/MY197116A/en unknown
- 2015-01-12 JP JP2016563278A patent/JP6479850B2/ja active Active
-
2016
- 2016-07-03 IL IL246575A patent/IL246575B/en active IP Right Grant
- 2016-07-07 PH PH12016501344A patent/PH12016501344A1/en unknown
-
2017
- 2017-08-02 US US15/667,173 patent/US10047104B2/en active Active
-
2018
- 2018-08-03 US US16/054,512 patent/US10640517B2/en active Active
- 2018-11-20 AU AU2018267569A patent/AU2018267569B2/en active Active
- 2018-12-21 CY CY20181101382T patent/CY1121433T1/el unknown
-
2019
- 2019-02-06 JP JP2019019229A patent/JP6750053B2/ja active Active
- 2019-12-11 IL IL271364A patent/IL271364B/en unknown
- 2019-12-17 AU AU2019283795A patent/AU2019283795B2/en active Active
-
2020
- 2020-02-19 US US16/795,394 patent/US10995100B2/en active Active
- 2020-03-13 PH PH12020500529A patent/PH12020500529A1/en unknown
- 2020-06-25 JP JP2020109507A patent/JP6977111B2/ja active Active
- 2020-11-23 ZA ZA2020/07275A patent/ZA202007275B/en unknown
- 2020-11-23 ZA ZA2020/07273A patent/ZA202007273B/en unknown
- 2020-11-23 ZA ZA2020/07274A patent/ZA202007274B/en unknown
- 2020-11-23 ZA ZA2020/07276A patent/ZA202007276B/en unknown
-
2021
- 2021-01-19 HR HRP20210094TT patent/HRP20210094T1/hr unknown
- 2021-01-29 CY CY20211100076T patent/CY1123936T1/el unknown
- 2021-04-30 US US17/245,611 patent/US11691987B2/en active Active
- 2021-06-08 AU AU2021203761A patent/AU2021203761B2/en active Active
- 2021-11-10 JP JP2021183016A patent/JP7262553B2/ja active Active
-
2023
- 2023-04-11 JP JP2023063800A patent/JP7601937B2/ja active Active
- 2023-04-28 US US18/141,008 patent/US11981685B2/en active Active
- 2023-09-01 AU AU2023222987A patent/AU2023222987B2/en active Active
-
2024
- 2024-04-08 US US18/629,313 patent/US12410193B2/en active Active
- 2024-12-05 JP JP2024211949A patent/JP7775430B2/ja active Active
-
2025
- 2025-08-04 US US19/289,386 patent/US20250361244A1/en active Pending
- 2025-09-04 AU AU2025226775A patent/AU2025226775A1/en active Pending
- 2025-11-12 JP JP2025191819A patent/JP2026027431A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017505337A5 (enExample) | ||
| ES2975436T3 (es) | Enantiómeros (R) y (S) de n-(5-(3-hidroxipirrolidin-1-il)-2-morfolinooxazolo[4,5-b]piridin-6-il)-2-(2-metilpiridin-4- il)oxazol-carboxamida como inhibidores de IRAK4 para el tratamiento del cáncer | |
| JP2017518348A5 (enExample) | ||
| CN105348266B (zh) | 取代的3‑氯‑n‑[3‑(嘧啶‑2‑基氨基)苯基]丙酰胺或其盐 | |
| JP2016531870A5 (enExample) | ||
| IL303987A (en) | IRAK joints and their uses | |
| ES2794779T3 (es) | Derivados de pirazolo[1,5-a]pirazin-4-ilo como inhibidores de JAK | |
| ES2600161T3 (es) | Compuestos para uso en el tratamiento de enfermedades mediadas por linfocitos T | |
| JP2015503618A5 (enExample) | ||
| JP6298830B2 (ja) | 治療用に活性なピラゾロ−ピリミジン誘導体 | |
| BR112020020196A2 (pt) | compostos que visam brm e métodos de uso associados | |
| RU2016140870A (ru) | Ингибиторы irak и их применения | |
| RU2016110852A (ru) | Ингибиторы irak и их применения | |
| AU2014324595A1 (en) | Substituted nicotinimide inhibitors of BTK and their preparation and use in the treatment of cancer, inflammation and autoimmune disease | |
| HK1231480A1 (zh) | 作为irak4抑制剂的吲唑化合物 | |
| CA2718528A1 (en) | Substituted 4-hydroxypyrimidine-5-carboxamides | |
| WO2021018118A1 (en) | Compounds and methods for the targeted degradation of interleukin-1 receptor-associated kinase 1 proteins | |
| TW200951139A (en) | Chemical compounds 293 | |
| US11753418B2 (en) | Compounds for the modulation of Myc activity | |
| CN113292536A (zh) | 一种具有降解Bcr-Abl或PARP的化合物及其制备方法和药学上的应用 | |
| CA2992981A1 (en) | Aminonaphthoquinone compounds and pharmaceutical composition for blocking ubiquitination-proteasome system in diseases | |
| CN105189497B (zh) | 作为janus激酶抑制剂的n-(2-氰基杂环基)吡唑并吡啶酮 | |
| CN112851668A (zh) | Atr抑制剂及其在医药上的应用 | |
| CA3003559A1 (en) | Fused thiazolopyrimidine derivatives as mnks inhibitors | |
| AU2024321427A1 (en) | Pharmaceutical compounds and compositions as c-kit kinase inhibitors |